Skip to content

Assessment of Neural Signals for the Control of Assistive Devices

Assessment of Neural Signals for the Control of Assistive Devices

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06533969
Enrollment
3
Registered
2024-08-01
Start date
2024-09-06
Completion date
2027-12-31
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury (SCI), Initial Encounter

Keywords

Brain Computer Interface, Epidural Spinal Cord Stimulation

Brief summary

The study will investigate the use of motor intention-based cortical signals to trigger epidural spinal cord stimulation (ESCS) with individuals with SCI. Motor intention of UL tasks will be decoded using brain-computer interface (BCI) system based on cortical signals recorded using an Electroencephalographic (EEG) system or using their intracranially implanted devices Electrocorticographic (ECoG).

Interventions

This will be a one time surgery lasting no more than 2 hours where ESCS electrodes will be connected to an external stimulator approved for human research. Stimulation intensity and parameters will be configured before each session for optimal upper extremity motor function. The ESCS approach will include surgical implantation of temporarily placed leads in the cervical epidural space and connection cables tunneled percutaneously through the skin for \<30 days

DEVICEElectrocorticographic

Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.

DEVICEElectroencephalographic

Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.

Sponsors

University of Miami
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients age 18 and older * Able to sign informed consent * Not participating in other studies that limit participation * Chronic (\>6 month) traumatic Spinal Cord Injury (SCI) (C4-T1 neurological injury with American Spinal Injury Association Impairment Scale (AIS A-D) with some residual function.

Exclusion criteria

* Patients that are pregnant * Patients under the age of 18 * Patients unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change in Hand Motor FunctionBaseline, up to 2 months post-implantToronto Rehabilitation Institute Hand Function Test (TRI-HFT): Measured on a scale from 0-133 to assess upper extremity manipulation and grip force at time points before and after implant. Higher scores indicate better hand motor function.
Change in Hand Motor Evoked Potential (MEP)Baseline, up to 2 months post-implantChange in Motor Evoked Potential (MEP): MEP evaluates corticospinal excitability (strength of the connections between the brain and the muscles). The excitability is measured as a peak-to-peak amplitude in millivolts (mV).

Secondary

MeasureTime frameDescription
Change in Movement KinematicsBaseline, up to 2 months post-implantKinematics data (motion capture, measured in centimeters) at time points before and after implant.
Change in Muscle StrengthBaseline, up to 2 months post-implantMuscle force testing: Assessment of changes in muscle strength from measured in Newtons at time points before and after implant.
Change in Quality of LifeBaseline, up to 2 months post-implantQuality of Life using the International Spinal Cord Injury - Quality of Life (ISCI-QOL): ISCI-QOL consists of three single items on satisfaction with life as a whole, physical health, and psychological health using a 0-10 scale where 0=complete dissatisfaction; 10=complete satisfaction. A composite score will be obtained for this measure.
Change in Graded and Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP)Baseline, up to 2 months post-implantGraded and Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP): Standardized test to be measured on a scale from 0-116 through the combination of five subset scores to assess grasping ability at time points before and after implant. A composite score will be obtained for strength, muscle force and tasks. Higher scores indicate better hand motor function.
Change in Satisfaction of LifeBaseline, up to 2 months post-implantMedical Outcomes Study Short Form 36 (SF-36): Patient-reported outcome measurement for health-related quality of life and activities of daily living scored on a scale of 0 (negative health) to 100 (positive health).
Change in Pain LevelsBaseline, up to 2 months post-implantBrief Pain Inventory (BPI): A questionnaire for pain will be assessed on a scale of 0 (no pain) to 10 (worst imaginable pain) at different points before and after the implant.
Change in Independence Measured by Spinal Cord Independence Measure (SCIM III)Baseline, up to 2 months post-implantIndependence as measured by Spinal Cord Independence Measure (SCIM III): SCIM III assesses performance in activities of daily living Scores range from 0-100, where a score of 0 defines total dependence and a score of 100 is indicative of complete independence.
Change in Muscle Coordination Measured by Electromyography (EMG)Baseline, up to 2 months post-implantFunctional tasks: Assessments to measure reaching ability and obtain muscle coordination via EMG (millivolts).

Countries

United States

Contacts

Primary ContactLetitia Fisher
lfisher@miami.edu305-243-3056
Backup ContactMatija Milosevic, PhD
mxm194475@miami.edu305-243-3572

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026